OBJECTIVE: To determine the value of positron emission tomography (PET) with contrast-enhanced computed tomography (CT) in assessing the need for neck dissection by retrospectively reviewing the pathology reports of patients with human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (SCC). DESIGN: Retrospective cohort study. SETTING: Tertiary medical center. PATIENTS: Seventy-seven patients with HPV-related SCC. MAIN OUTCOME MEASURES: Seventy-seven consecutive patients with a diagnosis of HPV-related SCC who were treated with radiotherapy as the primary treatment between August 2007 and October 2010 were retrospectively evaluated for radiologic and pathologic rate of persistence of nodal metastasis after completion of definitive radiotherapy. Pretreatment and posttreatment imaging included contrast-enhanced CT and PET. Response to treatment was measured on CT, PET at standardized uptake value (SUV) thresholds of 2 and 2.5, and PET/CT by a neuroradiologist in a blinded fashion. Then, the pathology report of the patients who underwent neck dissections was reviewed for nodal status after resection and correlated with the imaging findings. RESULTS: Of the 77 patients, 67 met the study criteria, with an average follow-up PET/CT scan at 90.5 days after completion of radiotherapy. Ten patients did not undergo follow-up PET/CT imaging. Twenty patients underwent neck dissections after completion of radiation therapy. Of these 20 patients, 4 had persistent tumor and 16 did not have viable tumor. Using the final pathology report to correlate with imaging responses, CT had a negative predictive value (NPV) of 85.7% (95% CI, 48.7%-97.4%), PET with SUV thresholds of 2 had an NPV of 91.7% (95% CI, 64.6%-98.5%), PET with a cutoff SUV of 2.5 had an NPV of 85.7% (95% CI, 60.1%-96.0%), PET/CT with an SUV of 2 had an NPV of 100% (95% CI, 59.8%-100.0%), and PET/CT with an SUV of 2.5 had an NPV of 85.7% (95% CI, 48.7%-97.4%). The 47 patients who did not undergo neck dissection had a median follow-up of 26 months without an isolated neck failure. Analysis of all 67 patients in the cohort revealed the following values: CT had an NPV of 95.7% (95% CI, 85.8%-98.8%), PET with an SUV of 2 had an NPV of 98.2% (95% CI, 90.4%-99.7%), PET with an SUV of 2.5 had an NPV of 95.0% (95% CI, 86.3%-98.3%), PET/CT with an SUV of 2 had an NPV of 100.0% (95% CI, 92.0%-100.0%), and PET/CT with an SUV of 2.5 had an NPV of 95.7% (95% CI, 85.8%-98.8%). CONCLUSIONS: Positron emission tomography combined with contrast-enhanced CT has a better NPV than either imaging modality alone in patients with HPV-associated oropharyngeal SCC. Furthermore, PET/CT with an SUV threshold of 2 used in patients with HPV-related SCC offers an imaging modality with a high NPV that may obviate the need for unnecessary neck dissections.
OBJECTIVE: To determine the value of positron emission tomography (PET) with contrast-enhanced computed tomography (CT) in assessing the need for neck dissection by retrospectively reviewing the pathology reports of patients with human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (SCC). DESIGN: Retrospective cohort study. SETTING: Tertiary medical center. PATIENTS: Seventy-seven patients with HPV-related SCC. MAIN OUTCOME MEASURES: Seventy-seven consecutive patients with a diagnosis of HPV-related SCC who were treated with radiotherapy as the primary treatment between August 2007 and October 2010 were retrospectively evaluated for radiologic and pathologic rate of persistence of nodal metastasis after completion of definitive radiotherapy. Pretreatment and posttreatment imaging included contrast-enhanced CT and PET. Response to treatment was measured on CT, PET at standardized uptake value (SUV) thresholds of 2 and 2.5, and PET/CT by a neuroradiologist in a blinded fashion. Then, the pathology report of the patients who underwent neck dissections was reviewed for nodal status after resection and correlated with the imaging findings. RESULTS: Of the 77 patients, 67 met the study criteria, with an average follow-up PET/CT scan at 90.5 days after completion of radiotherapy. Ten patients did not undergo follow-up PET/CT imaging. Twenty patients underwent neck dissections after completion of radiation therapy. Of these 20 patients, 4 had persistent tumor and 16 did not have viable tumor. Using the final pathology report to correlate with imaging responses, CT had a negative predictive value (NPV) of 85.7% (95% CI, 48.7%-97.4%), PET with SUV thresholds of 2 had an NPV of 91.7% (95% CI, 64.6%-98.5%), PET with a cutoff SUV of 2.5 had an NPV of 85.7% (95% CI, 60.1%-96.0%), PET/CT with an SUV of 2 had an NPV of 100% (95% CI, 59.8%-100.0%), and PET/CT with an SUV of 2.5 had an NPV of 85.7% (95% CI, 48.7%-97.4%). The 47 patients who did not undergo neck dissection had a median follow-up of 26 months without an isolated neck failure. Analysis of all 67 patients in the cohort revealed the following values: CT had an NPV of 95.7% (95% CI, 85.8%-98.8%), PET with an SUV of 2 had an NPV of 98.2% (95% CI, 90.4%-99.7%), PET with an SUV of 2.5 had an NPV of 95.0% (95% CI, 86.3%-98.3%), PET/CT with an SUV of 2 had an NPV of 100.0% (95% CI, 92.0%-100.0%), and PET/CT with an SUV of 2.5 had an NPV of 95.7% (95% CI, 85.8%-98.8%). CONCLUSIONS: Positron emission tomography combined with contrast-enhanced CT has a better NPV than either imaging modality alone in patients with HPV-associated oropharyngeal SCC. Furthermore, PET/CT with an SUV threshold of 2 used in patients with HPV-related SCC offers an imaging modality with a high NPV that may obviate the need for unnecessary neck dissections.
Authors: Min Yao; John M Buatti; Kenneth J Dornfeld; Michael M Graham; Russell B Smith; Gerry F Funk; Henry T Hoffman Journal: Int J Radiat Oncol Biol Phys Date: 2005-01-01 Impact factor: 7.038
Authors: H Minn; M Lapela; P J Klemi; R Grénman; S Leskinen; P Lindholm; J Bergman; E Eronen; M Haaparanta; H Joensuu Journal: J Nucl Med Date: 1997-12 Impact factor: 10.057
Authors: Laura A Goguen; Marshall R Posner; Roy B Tishler; Lori J Wirth; Charles M Norris; Donald J Annino; Christopher A Sullivan; Yi Li; Robert I Haddad Journal: Arch Otolaryngol Head Neck Surg Date: 2006-05
Authors: Sandro V Porceddu; Elizabeth Jarmolowski; Rodney J Hicks; Rob Ware; LeAnn Weih; Danny Rischin; June Corry; Lester J Peters Journal: Head Neck Date: 2005-03 Impact factor: 3.147
Authors: Musaddiq J Awan; Pierre Lavertu; Chad Zender; Rod Rezaee; Nicole Fowler; Lilit Karapetyan; Michael Gibson; Jay Wasman; Peter Faulhaber; Mitchell Machtay; Min Yao Journal: Eur J Nucl Med Mol Imaging Date: 2017-01-14 Impact factor: 9.236
Authors: Jeffrey M Vainshtein; Matthew E Spector; Matthew H Stenmark; Carol R Bradford; Gregory T Wolf; Francis P Worden; Douglas B Chepeha; Jonathan B McHugh; Thomas Carey; Ka Kit Wong; Avraham Eisbruch Journal: Oral Oncol Date: 2013-12-31 Impact factor: 5.337
Authors: Joshua K Cho; Thomas J Ow; Andrew Y Lee; Richard V Smith; Nicolas F Schlecht; Bradley A Schiff; Andrew B Tassler; Juan Lin; Renee M Moadel; Ana Valdivia; Tony Abraham; Edwin Gulko; Matthew Neimark; Berrin Ustun; Jacqueline A Bello; Keivan Shifteh Journal: Otolaryngol Head Neck Surg Date: 2017-06-13 Impact factor: 3.497
Authors: Travis C Salzillo; Nicolette Taku; Kareem A Wahid; Brigid A McDonald; Jarey Wang; Lisanne V van Dijk; Jillian M Rigert; Abdallah S R Mohamed; Jihong Wang; Stephen Y Lai; Clifton D Fuller Journal: Semin Radiat Oncol Date: 2021-10 Impact factor: 5.421
Authors: Yan Li; Musaddiq J Awan; Tangel Chang; Pierre Lavertu; Chad Zender; Rod Rezaee; Nicole Fowler; Jay Wasman; Norbert E Avril; Nianyong Chen; Mitchell Machtay; Min Yao Journal: Eur J Nucl Med Mol Imaging Date: 2019-01-24 Impact factor: 9.236
Authors: Nils Helsen; Tim Van den Wyngaert; Laurens Carp; Remco De Bree; Olivier M VanderVeken; Frank De Geeter; Alex Maes; Jean-Philippe Cambier; Karoline Spaepen; Michel Martens; Sara Hakim; Laurence Beels; Otto S Hoekstra; Danielle Van den Weyngaert; Sigrid Stroobants; Carl Van Laer; Pol Specenier; Annelies Maes; Philip Debruyne; Isabel Hutsebaut; Joost Van Dinter; Filip Homans; Laurence Goethals; Oliver Lenssen; Kristof Deben Journal: Eur J Nucl Med Mol Imaging Date: 2020-02-10 Impact factor: 9.236
Authors: S Connor; C Sit; M Anjari; M Lei; T Guerrero-Urbano; T Szyszko; G Cook; P Bassett; V Goh Journal: J Cancer Res Clin Oncol Date: 2021-06-22 Impact factor: 4.553